VSTM - Verastem, Inc. Debt to Book Capitalization Ratio

Verastem, Inc. (VSTM) management effectively manages its portfolio of targeted inhibitors and ensures transparency of clinical processes at the 1.65 level. This chart of share price dynamics allows for an assessment of the market reaction to drug development in US centers for the treatment of rare tumors. The company's potential competitive advantage relies on patent protection for combined ovarian cancer therapy methods.

VSTM Verastem, Inc.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Verastem Oncology (VSTM)

- price and consensus price forecast:

Stock Price Verastem, Inc.|VSTM - Consensus Target

- market capitalization data:

Market Value Verastem Corp|VSTM - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Verastem|VSTM - Company Book Value|Market Value to Book Value Ratio verastem.com|VSTM - Company Assets

- debt and liquidity data:

Total Debt to Capital Verastem, Inc.|VSTM - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Verastem Inc|VSTM - Company Cumulative Debt|Debt to Book Value Verastem Corp

Analysis of all company metrics:VSTM, Verastem, Inc.

This ratio measures the proportion of debt obligations within the equity structure, allowing for an assessment of financial stability and bankruptcy risk through the debt-to-book value ratio. By analyzing the debt of Verastem, Inc. (VSTM) relative to its book capitalization, an investor can determine the valuation's sensitivity to new loans required by Verastem, Inc. (VSTM) to fund costly clinical trials and protect oncology patents.

Competitors of Verastem, Inc. (VSTM)